JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Hospital Universitario Puerta del Mar
Cádiz, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Puerta del Mar (5)
2022
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
2020
-
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270
2017
-
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice
British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970
2015
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211